ACL Stock Overview
Australian Clinical Labs Limited provides pathology services in Australia.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 4/6 |
| Past Performance | 1/6 |
| Financial Health | 4/6 |
| Dividends | 1/6 |
Australian Clinical Labs Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$2.43 |
| 52 Week High | AU$3.70 |
| 52 Week Low | AU$2.26 |
| Beta | 1.17 |
| 1 Month Change | -4.33% |
| 3 Month Change | -17.63% |
| 1 Year Change | -30.37% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -30.07% |
Recent News & Updates
Recent updates
Shareholder Returns
| ACL | AU Healthcare | AU Market | |
|---|---|---|---|
| 7D | 0.8% | 1.2% | 1.8% |
| 1Y | -30.4% | -20.2% | 7.0% |
Return vs Industry: ACL underperformed the Australian Healthcare industry which returned -19.5% over the past year.
Return vs Market: ACL underperformed the Australian Market which returned 8.1% over the past year.
Price Volatility
| ACL volatility | |
|---|---|
| ACL Average Weekly Movement | 4.7% |
| Healthcare Industry Average Movement | 7.0% |
| Market Average Movement | 9.0% |
| 10% most volatile stocks in AU Market | 17.2% |
| 10% least volatile stocks in AU Market | 3.5% |
Stable Share Price: ACL's share price has been volatile over the past 3 months.
Volatility Over Time: ACL's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2020 | 5,115 | Melinda McGrath | www.clinicallabs.com.au |
Australian Clinical Labs Limited provides pathology services in Australia. The company offers range of services, which include routine pathology test, advanced molecular genetics testing, harmony NIPT and first trimester screening, genetic carrier screening, chemical pathology, histopathology, and cytopathology; hematology, allergy, and immunology; serology and microbiology; and infectious molecular testing, cardiac testing services, functional pathology, veterinary pathology, and commercial drug and alcohol testing services. It offers its service to private and public hospitals.
Australian Clinical Labs Limited Fundamentals Summary
| ACL fundamental statistics | |
|---|---|
| Market cap | AU$487.22m |
| Earnings (TTM) | AU$15.43m |
| Revenue (TTM) | AU$674.03m |
31.6x
P/E Ratio0.7x
P/S RatioIs ACL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ACL income statement (TTM) | |
|---|---|
| Revenue | AU$674.03m |
| Cost of Revenue | AU$434.62m |
| Gross Profit | AU$239.40m |
| Other Expenses | AU$223.97m |
| Earnings | AU$15.43m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.077 |
| Gross Margin | 35.52% |
| Net Profit Margin | 2.29% |
| Debt/Equity Ratio | 47.7% |
How did ACL perform over the long term?
See historical performance and comparison